Financials data is unavailable for this security.
View more
Year on year J B Chemicals and Pharmaceuticals Ltd grew revenues 10.63% from 31.49bn to 34.84bn while net income improved 34.84% from 4.10bn to 5.53bn.
| Gross margin | 66.27% |
|---|---|
| Net profit margin | 16.34% |
| Operating margin | 22.20% |
| Return on assets | -- |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in INRView more
In 2024, J B Chemicals and Pharmaceuticals Ltd increased its cash reserves by 14.66%, or 112.81m. The company earned 8.01bn from its operations for a Cash Flow Margin of 22.98%. In addition the company used 4.04bn on investing activities and also paid 3.85bn in financing cash flows.
| Cash flow per share | 46.26 |
|---|---|
| Price/Cash flow per share | 39.25 |
| Book value per share | -- |
|---|---|
| Tangible book value per share | -- |
More ▼
Balance sheet in INRView more
| Current ratio | -- |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
Growth rates in INR
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 38.03% and 33.17%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth is above the industry average relative to its peers, while earnings per share growth is in-line with the industry average.
| Div yield(5 year avg) | 1.23% |
|---|---|
| Div growth rate (5 year) | 37.42% |
| Payout ratio (TTM) | 17.84% |
| EPS growth(5 years) | 24.25 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 29.55 |
More ▼
